香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公告乃遠大醫藥集團有限公司(「本公司」，連同其附屬公司統稱「本集團」)之董事 會(「董事會」)自願刊發。 董事會欣然公告，本集團引進的用於治療蠕形蟎瞼緣炎的全球創新眼科藥物 GPN01768 [TP-03，(洛替拉納滴眼液) 0.25%]近日正式獲得中華人民共和國國家藥品監督管理局 (「藥監局」)頒發的藥品註冊證書，且在藥品審評過程中未收到補充資料通知，實現「零 發補」獲批上市。本集團於二零二四年三月與 Tarsus Pharmaceuticals, Inc. (「Tarsus Pharmaceuticals」，TP-03 的開發者)達成產品引進戰略合作協議，獲得在大中華區（中 國大陸、中國香港特別行政區、中國澳門特別行政區、中國台灣地區）的獨家開發、生 產及商業化權益。此次該產品獲批上市是本集團在五官科板塊眼科創新藥方向上的又一 項重要進展。 蠕形蟎是導致蠕形蟎瞼緣炎的根本原因，GPN01768 是一 ...

Summary of the Conference Call for Xingqi Eye Pharmaceutical Company Overview - **Company**: Xingqi Eye Pharmaceutical - **Industry**: Ophthalmic Pharmaceuticals Key Financial Performance - **Revenue**: 11.62 billion CNY in H1 2025, a year-on-year increase of 30.38% [2][3] - **Net Profit**: 3.35 billion CNY, a year-on-year increase of 97.75% [2][3] - **Dividend Proposal**: Cash dividend of 7 CNY per 10 shares, subject to shareholder approval [2][3] Research and Development Progress - **R&D Investment**: 1.0 billion CNY, an increase of 8.11%, representing 8.64% of revenue [2][4] - **Product Approvals**: - Heafluprost eye drops approved - Lidocaine eye gel in Phase III clinical trials - SQ22,031 eye drops in Phase II clinical trials for neurotrophic keratitis, listed as a rare disease drug [2][4][5] - **Innovative Products**: - 60 approved ophthalmic drugs, with 38 in the medical insurance directory and 6 in the national essential drug list [4] - SQ22,031 eye drops and SQ129 vitreous sustained-release injection under development [9] Market Strategy and Sales Performance - **Atropine Sales**: - Widely distributed in public hospitals and major private groups, covering nearly 17,000 retail pharmacies and online platforms [2][10] - Sales growth driven by a comprehensive marketing strategy and collaboration in myopia prevention [12] - **Sales Team**: Over 500 professional promotion specialists, with plans for further expansion based on market conditions [10][12] - **Market Coverage**: - Multi-channel marketing strategy including both online and offline channels [12][18] - Focus on enhancing brand influence and customer satisfaction [7][8] Future Outlook and Market Trends - **Market Potential**: - Significant growth potential in the myopia prevention market, with over 100 million schoolchildren affected [24] - Anticipated stable gross margin due to increased sales scale and operational efficiency [21] - **Product Pipeline**: - Continued focus on innovative drug development in ophthalmology, including treatments for myopia, dry eye, and other eye diseases [23][25] - Plans to expand into international markets with existing and new products [22] Additional Insights - **Quality Management**: - Achieved national-level green factory certification and implemented stringent quality control measures [6] - **Patient Compliance**: - High compliance rates among pediatric patients using atropine, with ongoing efforts to improve disease education and treatment adherence [18][19] - **Clinical Guidelines**: - Received endorsements from multiple clinical guidelines, enhancing the credibility of products like cyclosporine eye drops [20] This summary encapsulates the key points from the conference call, highlighting the financial performance, R&D advancements, market strategies, and future outlook for Xingqi Eye Pharmaceutical.

Group 1 - The core point of the article is that Renhe Pharmaceutical's joint venture Chengdu Ruimu has made significant progress in the clinical trial of its innovative drug RM301B, which is currently in the process of developing a phase II clinical plan [1][3] - RM301B is a groundbreaking ophthalmic drug developed by Chengdu Ruimu, a high-tech biopharmaceutical company founded by overseas returnees, focusing on new technologies and products in ophthalmology [3] - The company is in negotiations regarding whether it will exclusively market RM301B and other new products, which, if successful, is expected to have a positive impact on the company's performance [1][3]